ASX biotech shares have had an up and down start to the year. While the S&P/ASX 200 Index (ASX: XJO) is up 1.8%, shares in Pro Medicus Limited (ASX: PME) and Polynovo Ltd (ASX: PNV) have been far more volatile.
Why ASX biotech shares are up and down in 2021
On the one hand, the Pro Medicus share price has climbed 28.5% and raced to a new all-time high. The company’s fifth major contract win in sixth months was a key factor.
Pro Medicus has signed a 7-year, $40 million contract with Salt Lake City-based Intermountain Healthcare. That will see its Visage 7 Viewer and Visage 7 Open Archive products implemented across all of Intermountain’s radiology and subspecialty imaging departments.
However, it hasn’t been all good news for investors in ASX biotech shares this year. While Pro Medicus shares soar, the Polynovo share price has fallen 35.9% this year.
Polynovo develops biodegradable medical devices that aid in skin tissue repair, led by its flagship Novosorb polymer. An important trading update on January 12 has been the catalyst for the ASX biotech share price slump this year.
Interestingly, Polynovo shares have fallen sharply despite a number of sales updates in recent months.
Polynovo reported a 31% increase in sales over the prior corresponding period (pcp) for the first half of FY21. The Aussie biotech’s near term performance could be “volatile”, according to managing director, Paul Brennan. Sales also slowed in October and November despite an uptick to finish the year.
The ASX biotech share soared in 2020 meaning some profit-taking may also be pushing the share price down.
Combined with the short-term uncertainty and ongoing impact of the coronavirus pandemic, the Polynovo share price has been under pressure to start the year.
Foolish takeaway
2021 has been the tale of two ASX biotech shares. While Pro Medicus shares soar, the Polynovo share price has been smashed this year.
Both companies are yet to report their half-year results to the market which are expected later this month.
Our TOP healthcare stock is trading at a 15% discount to its highs
If there’s one thing for sure, 2020 was the year we embraced sanitisation. Scott Phillips has discovered a little-known Australian healthcare company could be set to reap the rewards of the post-covid world.
Better yet, this fast-growing company is currently trading at a 15% discount from its highs. Scott believes in this stock so much, he’s staked $209k of our own company money on it. Forget ‘buy now pay later’, this stock could be the next hot stock on the ASX.
Scott and his team have published a detailed report on this tiny ASX stock. Find out how you can access our TOP healthcare stock today!
Find out the name of this stock
As of 15.02.2021
More reading
- Why ASX travel shares were smashed on Friday
- ASX 200 Weekly Wrap: ASX cools on earnings reality check
- 5 things to watch on the ASX 200 on Monday
- 5 things to watch on the ASX 200 next week
- These were the best performing ASX 200 shares last week
Ken Hall has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and recommends Pro Medicus Ltd. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of POLYNOVO FPO. The Motley Fool Australia has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
The post A turbulent tale of 2 ASX biotech shares: Polynovo (ASX:PNV) and Pro Medicus (ASX:PME) appeared first on The Motley Fool Australia.
from The Motley Fool Australia https://ift.tt/3ddbnBX
Leave a Reply